Ian J. Jacobs
Oxford University Press, 2002 - Medical - 427 pages
Ovarian cancer provides an up-to-date and comprehensive synthesis of clinical management and research progress in the field of epithelial ovarian cancer. The book has its origins in two separate but complementary initiatives. One initiative was a series of reviews commissioned to cover the spectrum of clinical management of ovarian cancer from prevention, screening and diagnosis to surgery, chemotherapy and palliative care. The reviews were invited from an international panel of clinicians with expertise in the management of ovarian cancer. The second initiative was co-ordinated by the Helene Harris Memorial Trust (HHMT) which has organised key biennial meetings on ovarian cancer for the last 12 years. Attendance at the meetings is by invitation to a small group of international authorities on research aspects of ovarian cancer. Setting the clinically focused reviews alongside the HHMT research focused chapters has created a unique book. First, the book is unusually up-to-date and presents recent advances not included in other books in this field. Second, the contents are comprehensive and cover aetiology, pathology, screening, prevention, diagnosis, prognostic techniques, surgery, adjuvant therapy and palliative care. Third, the review chapters are set alongside more detailed coverage of recent clinical and basis science developments. Examples of this are the coverage of familial cancer, prevention, screening, and current therapy which are consequently much more topical and exciting. Fourth, there are sections on 'tumour biology' and 'novel therapies' which have not been covered in comparable books about ovarian cancer. Finally, the contributions are from a representative spectrum of experts from both research and clinical backgrounds and with a truly international perspective.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Daniel W Cramer
The application of novel technology to the study
Overview of the aetiology of familial ovarian cancer
15 other sections not shown
activity adenocarcinoma analysis angiogenesis antibody antigen apoptosis ARHI associated benign borderline malignancy BRCA1 BRCA2 BRCAl breast cancer CA125 levels Cancer Res carriers cell carcinoma cell lines cell tumours chemopreventive chemotherapy chromosome cisplatin Clin clinical color Doppler cysts cytoreductive debulking detection diagnosis differentiation disease endometrioid epithelial cells epithelial ovarian cancer epithelium evaluation expression familial ovarian cancer family history genetic germ cell tumours granulosa cell granulosa cell tumors growth factor Gynecol Gynecologic histological hormone human ovarian increased invasive laparoscopy lesions markers metastatic molecular mucinous neoplasms normal Obstet Oncol Oncology ovarian cancer risk ovarian cancer screening ovarian carcinoma ovarian epithelial ovarian tumors ovary overexpression ovulation paclitaxel Pathol patients pelvic peritoneal postmenopausal primary progestin prophylactic oophorectomy protein receptor reported risk of ovarian serous stage stromal suppressor gene surface epithelial surgery survival telomerase therapy tion tissue transvaginal treatment trial tumor suppressor gene ultrasound vascular VEGF women